In 2010, MSF treated over 30,000 people suffering from tuberculosis (TB). Long neglected by research efforts, patients are now able to enjoy the benefits of recent innovation.
At the beginning of 2013, MSF applauded the promising results of Bedaquiline, a drug tested against drug-resistant TB.
The drug is still at the clinical evaluation stage but given the abysmal lack of treatment options, it has received authorisation for so-called compassionate-use, meaning when all other existing treatments have failed. In Armenia, 15 patients are thus being treated with Bedaquiline.